NCT01605396 2019-03-25
MK-8669-064
Merck Sharp & Dohme LLC
Phase 2 Completed
Clinical Trials
11 trialsNCT00836927 2019-02-18
MK-8669-038
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00110188 2015-11-20
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00736970 2015-08-27
Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00086125 2015-08-19
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00777959 2015-08-19
Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00739830 2015-07-01
Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01010672 2015-04-30
Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00122343 2015-02-19
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00093080 2015-02-13
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00818675 2015-01-21
A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)
Merck Sharp & Dohme LLC
Phase 2 Terminated